Abstract

Aeras is a fully integrated, global, nonprofit biotech with capabilities in finance, portfolio management, immunology, assay development, clinical trials, regulatory affairs and policy, advocacy, and resource mobilization, as well as in-house capacity to conduct pilot manufacturing. Serving as a critical translational bridge from the bench to the field Aeras has sponsored and conducted more than 25 clinical vaccine trials enrolling thousands of subjects and is a key partner in six active clinical development programs.

Mission

The Aeras mission is to develop new tuberculosis (TB) vaccines that are affordable and accessible to all who need them.

Structure & Governance
Board of Directors

Financing

Aeras R&D work is funded by key partners worldwide. Funding streams include grants from foundations and governments, investments from industry partners, and co-investments with other organizations, governments, and institutions.

Donor support drives innovation by strengthening and advancing the global pipeline of new TB vaccines, accelerating efforts toward ensuring their availability to all who need them.

Data Sharing

TB vaccine research and development is complex and costly. No one organization or institution can do it alone. Aeras works in partnership with individuals, research organizations, academic institutions, funders, policymakers, and others to advance TB vaccine science. Because of limited resources and the complex biology of TB, it is crucial for scientists in this field to share knowledge and work together.

Some of Aeras’ partners include the following:

Impact/Accomplishment

Aeras’ global partners include academic, public, and private institutions, which work together to build research capacity, install diagnostic and immunology lab infrastructure, and provide training and employment to world-class researchers.

South Africa is particularly poised as a key driver of TB vaccine innovation, because it has the highest incidence of the disease and is well-equipped with world-renowned researchers and infrastructure to conduct TB studies. Aeras’ in-country partners provide primary and follow-up care to communities involved in clinical trials. They educate the local communities and raise awareness about TB and vaccine trials.
Recently, the successful completion of the first large, Phase IIb trial in South Africa of nearly 3,000 infants showed that it is possible to conduct a trial of that scope and magnitude, even though the vaccine did not prove to be more efficacious than the widely used infant vaccine BCG.

Links/Social Media Feed

Homepage  http://www.aeras.org/
Twitter  https://twitter.com/aerasglobaltb
Facebook  https://www.facebook.com/AerasGlobalTB

Sponsors & Partners

Albert Einstein College of Medicine
Australian AID
Bill & Melinda Gates foundation
Chinese Center for Disease Control and Prevention
Colorado State University
Columbia University
Cornell University
Crucell

Dartmouth University
EDCTP

U.S. Food and Drug Administration
Fudan University
GHIT Fund
GlaxoSmithKline
Harvard University
Huazhong Agricultural University
Imperial College London
Infectious Disease Research Institute
Institute Pasteur de Lille
Johns Hopkins University
London School of Hygiene & Tropical Medicine
Maastricht University
National Institute of Allergy and Infectious Diseases
Okairos
Oregon Health & Science University
Pontificia Universidad Catolica de Chile
Rijksoverheid
Rutgers University
Sanofi Pasteur

South African Tuberculosis Vaccine Initiative
(satvi)
St. Louis University
Statens Serum Institut
StopTBPartnership

Tuberculosis Vaccine Initiative
Tulane University
UKaid
Universita Cattolica del Sacro Cuore
University of Alberta
University of British Columbia
University of California, Berkeley
University of California, Los Angeles
University of Cape Town
University of Maryland
University of Oxford
University of Pittsburgh
University of Sydney
University of Wales
University of Wisconsin
WellcomeTrust

Wuhan University